Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Data on cancer vaccines detailed by researchers at INSERM
January 27th, 2009
New research, 'HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine,' is the subject of a report. According to recent research from Saint-Herblain, France, "Vaccination with full-length human tumor antigens aims at inducing or increasing antitumor immune responses, including CD8 CTL in cancer patients across the HLA barrier. We have recently reported that vaccination with a recombinant tumor-specific NY-ESO-1 (ESO) protein, administered with Montanide and CpG resulted in the induction of specific integrated antibody and CD4 T cell responses in all vaccinated patients examined, and significant CTL responses in half of...
Source: Cancer Weekly (2009-01-27)
|
